Conference/Events
|
Tech 2022: Themes in a… Tech 2022: Themes in a Stock Picker's Market to be held on March 29.Webcast Link ShowHide Related Items >><< - 03/22/22
- RealReal provides long-range financial targets for FY25
- 01/05/22
- RealReal reports December GMV $153M, up 40% y/y, to resume quarterly updates
- 12/17/21
- RealReal provides notice of proposed settlement of derivative action
- 12/02/21
- RealReal reports November GMV $146M
- 02/28/22
- Forian says Florida chooses BioTrack as cannabis track, trace system
- 03/04/22
- Equillium initiates EQUATOR study
- 02/16/22
- Equillium acquires Bioniz Therapeutics, announced departure of CMO Dolca Thomas
- 11/02/21
- Equillium data shows itolizumab is well tolerated, reduces proteinuria
DOC Physicians Realty Trust - 02/23/22
- Physicians Realty Trust sees FY22 capital expenditures $40M-$42M
- 10/01/21
- Physicians Realty Trust acquires medical office buildings for $764M
- 03/09/22
- Docebo names Sukaran Mehta CFO
- 01/24/22
- Docebo acquires Skillslive, terms undisclosed
- 01/18/22
- Docebo, Pavilion enter strategic partnership to enhance learner experience
- 01/12/22
- Docebo appoints Enis Konuk as chief product officer
- 10/14/21
- CTS Corporation falls -6.5%
- 10/14/21
- CTS Corporation falls -4.4%
- 01/18/22
- Celestica's U.S. facility certified to ISO 13485 for medical device manufacture
- 12/02/21
- Celestica announces TSX acceptance of normal course issuer bid
- 11/01/21
- Celestica completes acquisition of PCI Private Limited
- 10/26/21
- Celestica rises 10.6%
- $192.69 /
+1.685 (+0.88%) - 02/07/22
- TopBuild acquires Billings Insulation
- 01/06/22
- TopBuild acquires Insulating Products
- 10/18/21
- TopBuild sees DI acquisition accretive to GAAP EPS in first year after close
- 10/06/21
- TopBuild acquires California Building Products, no terms
- 03/07/22
- Absolute Software CFO Steven Gatoff departs, Ron Fior named interim CFO
- 02/09/22 BMO Capital
- Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital
- 02/09/22 TD Securities
- TD Securities upgrades Absolute Software to Buy after 'another' beat and raise
- 02/09/22 TD Securities
- Absolute Software upgraded to Buy from Hold at TD Securities
- 08/11/21 BMO Capital
- Absolute Software price target lowered to C$18.50 from C$20 at BMO Capital
AIF Acceptance Insurance Group - $192.69 /
+1.685 (+0.88%) - 01/19/22 KeyBanc
- TopBuild downgraded to Sector Weight from Overweight at KeyBanc
- 12/23/21
- Fly Intel: Top five analyst upgrades
- 12/23/21 Zelman
- TopBuild upgraded to Buy from Hold at Zelman
- 12/03/21
- Fly Intel: Top five analyst downgrades
- 01/28/22 Canaccord
- Celestica price target raised to $13.50 from $12 at Canaccord
- 09/23/21 Citi
- Celestica price target raised to $8.50 from $8 at Citi
- 05/25/21 Stifel
- Plexus warning may be signal that supply constraints will worsen, says Stifel
- 01/31/22 Sidoti
- CTS Corporation upgraded to Buy from Neutral at Sidoti
- 10/14/21 Cowen
- CTS downgraded to Market Perform amid rising input costs at Cowen
- 10/14/21 Cowen
- CTS Corporation downgraded to Market Perform from Outperform at Cowen
- 12/13/21 UBS
- Cenveo initiated with a Neutral at UBS
- 03/11/22 Canaccord
- Docebo price target lowered to $65 from $80 at Canaccord
- 02/01/22 Canaccord
- Docebo price target lowered to $80 from $95 at Canaccord
- 01/10/22 CIBC
- Docebo price target lowered to C$102 from C$125 at CIBC
- 12/02/21 Stifel
- Docebo initiated with a Buy at Stifel
DOC Physicians Realty Trust - 02/28/22 BMO Capital
- BMO can't rule out topping bid for Healthcare Trust
- 02/01/22 Credit Suisse
- Physicians Realty Trust initiated with a Neutral at Credit Suisse
- 01/07/22 BMO Capital
- Physicians Realty Trust downgraded to Market Perform from Outperform at BMO Capital
- 10/07/21 BMO Capital
- Healthcare Trust price target raised to $35 from $32.50 at BMO Capital
- 02/11/22 Needham
- ChannelAdvisor price target lowered to $26 from $35 at Needham
- 02/02/22 B. Riley
- ChannelAdvisor price target lowered to $32 from $38 at B. Riley
- 12/29/21 Baird
- Baird announces three new top internet stock picks for 2022
- 09/20/21 Needham
- ChannelAdvisor price target raised to $35 from $31 at Needham
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 02/16/22 Stifel
- Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
- 01/12/22 Stifel
- Equillium 'could be upside biased' into lupus nephritis data, says Stifel
- 10/29/21 Stifel
- Equillium resumed with a Buy at Stifel
- 03/22/22 UBS
- RealReal price target lowered to $9 from $17 at UBS
- 03/17/22 Jefferies
- RealReal initiated with a Buy at Jefferies
- 03/17/22 Jefferies
- RealReal initiated with a Buy at Jefferies
- 02/24/22 Wedbush
- RealReal price target lowered to $14 from $21 at Wedbush
- 02/23/22
- RealReal sees FY22 revenue $635M-$665M, consensus $597.61M
- 02/23/22
- RealReal sees Q1 revenue $130M-$140M, consensus $134.27M
- 02/23/22
- RealReal reports Q4 EPS (42c), consensus (38c)
- 02/23/22
- Notable companies reporting after market close
- 03/23/22
- Equillium reports Q4 EPS (36c), consensus (34c)
- 11/10/21
- Equillium reports Q3 EPS (35c), consensus (34c)
- 02/10/22
- ChannelAdvisor sees Q1 revenue $41.9M-$42.3M, consensus $42.07M
- 02/10/22
- ChannelAdvisor reports Q4 EPS $1.06 with items, consensus 24c
- 11/09/21
- ChannelAdvisor reports Q3 EPS 11c, consensus 17c
DOC Physicians Realty Trust - 02/23/22
- Physicians Realty Trust reports Q4 EPS 26c, consensus 26c
- 11/05/21
- Physicians Realty Trust reports Q3 normalized FFO 26c, consensus 26c
- 11/11/21
- Docebo reports Q3 EPS 2c, consensus (5c)
- 02/08/22
- CTS Corporation sees FY22 adjusted EPS $2.00-$2.25, consensus $2.09
- 02/08/22
- CTS Corporation reports Q4 adjusted EPS 49c, consensus 47c
- 10/27/21
- CTS Corporation raises 2021 adjusted EPS view $1.85-$1.95 from $1.70-$1.90
- 10/27/21
- CTS Corporation reports Q3 adjusted EPS 46c, consensus 39c
- 03/24/22
- Celestica sees 2022 revenue over $6.3B, consensus $6.34B
- 01/26/22
- Celestica sees FY22 revenue at least $6.3B, consensus $6.34B
- 01/26/22
- Celestica sees Q1 adjusted EPS 31c-37c
- 01/26/22
- Celestica reports Q4 adjusted EPS 44c, consensus 32c
- $192.69 /
+1.685 (+0.88%) - 02/22/22
- TopBuild sees 2022 revenue $4.5B-$4.65B, consensus $4.51B
- 02/22/22
- TopBuild reports Q4 adjusted EPS $3.12, consensus $2.92
- 11/02/21
- TopBuild sees FY21 revenue $3.425B-$3.475B, consensus $3.42B
- 11/02/21
- TopBuild reports Q3 adjusted EPS $2.95, consensus $3.04
- 02/08/22
- Absolute Software raises FY22 revenue view to $206M-$208M, consensus $206.04M
- 02/08/22
- Absolute Software reports Q2 EPS (10c), consensus (8c)
- 11/29/21
- Citron keeps $30 target on RealReal, sees possible takeout
- 11/24/21
- RealReal will be at $30 in next 12 months 'if not acquired first,' Citron tweets
- 03/22/22
- What You Missed On Wall Street On Tuesday
- 03/22/22
- What You Missed On Wall Street This Morning
- 11/29/21
- Wall Street in Fives - Must Read Lists for Monday
- 11/29/21
- Wall Street in Fives - Must Read Lists at Midday
- 01/04/22
- Game On: Square Enix sees NFTs in games as 'major trend'
- 03/24/22
- What You Missed On Wall Street On Thursday
- 03/24/22
- What You Missed On Wall Street This Morning
- 12/01/21
- Wall Street in Fives - Must Read Lists at Midday
- 02/23/22
- RealReal options imply 16.4% move in share price post-earnings
- 11/08/21
- RealReal options imply 15.0% move in share price post-earnings
DOC Physicians Realty Trust - 12/15/21
- Unusual call flow in option market yesterday
- 12/14/21
- Call buyer targets 4 month 9.5% upside in Physicians Realty Trust
|
Conference/Events
|
Tech 2022: Themes in a… Tech 2022: Themes in a Stock Picker's Market to be held on March 29.Webcast Link ShowHide Related Items >><< - 03/22/22
- RealReal provides long-range financial targets for FY25
- 01/05/22
- RealReal reports December GMV $153M, up 40% y/y, to resume quarterly updates
- 12/17/21
- RealReal provides notice of proposed settlement of derivative action
- 12/02/21
- RealReal reports November GMV $146M
- 02/28/22
- Forian says Florida chooses BioTrack as cannabis track, trace system
- 03/04/22
- Equillium initiates EQUATOR study
- 02/16/22
- Equillium acquires Bioniz Therapeutics, announced departure of CMO Dolca Thomas
- 11/02/21
- Equillium data shows itolizumab is well tolerated, reduces proteinuria
DOC Physicians Realty Trust - 02/23/22
- Physicians Realty Trust sees FY22 capital expenditures $40M-$42M
- 10/01/21
- Physicians Realty Trust acquires medical office buildings for $764M
- 03/09/22
- Docebo names Sukaran Mehta CFO
- 01/24/22
- Docebo acquires Skillslive, terms undisclosed
- 01/18/22
- Docebo, Pavilion enter strategic partnership to enhance learner experience
- 01/12/22
- Docebo appoints Enis Konuk as chief product officer
- 10/14/21
- CTS Corporation falls -6.5%
- 10/14/21
- CTS Corporation falls -4.4%
- 01/18/22
- Celestica's U.S. facility certified to ISO 13485 for medical device manufacture
- 12/02/21
- Celestica announces TSX acceptance of normal course issuer bid
- 11/01/21
- Celestica completes acquisition of PCI Private Limited
- 10/26/21
- Celestica rises 10.6%
- $192.69 /
+1.685 (+0.88%) - 02/07/22
- TopBuild acquires Billings Insulation
- 01/06/22
- TopBuild acquires Insulating Products
- 10/18/21
- TopBuild sees DI acquisition accretive to GAAP EPS in first year after close
- 10/06/21
- TopBuild acquires California Building Products, no terms
- 03/07/22
- Absolute Software CFO Steven Gatoff departs, Ron Fior named interim CFO
- 02/09/22 BMO Capital
- Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital
- 02/09/22 TD Securities
- TD Securities upgrades Absolute Software to Buy after 'another' beat and raise
- 02/09/22 TD Securities
- Absolute Software upgraded to Buy from Hold at TD Securities
- 08/11/21 BMO Capital
- Absolute Software price target lowered to C$18.50 from C$20 at BMO Capital
AIF Acceptance Insurance Group - $192.69 /
+1.685 (+0.88%) - 01/19/22 KeyBanc
- TopBuild downgraded to Sector Weight from Overweight at KeyBanc
- 12/23/21
- Fly Intel: Top five analyst upgrades
- 12/23/21 Zelman
- TopBuild upgraded to Buy from Hold at Zelman
- 12/03/21
- Fly Intel: Top five analyst downgrades
- 01/28/22 Canaccord
- Celestica price target raised to $13.50 from $12 at Canaccord
- 09/23/21 Citi
- Celestica price target raised to $8.50 from $8 at Citi
- 05/25/21 Stifel
- Plexus warning may be signal that supply constraints will worsen, says Stifel
- 01/31/22 Sidoti
- CTS Corporation upgraded to Buy from Neutral at Sidoti
- 10/14/21 Cowen
- CTS downgraded to Market Perform amid rising input costs at Cowen
- 10/14/21 Cowen
- CTS Corporation downgraded to Market Perform from Outperform at Cowen
- 12/13/21 UBS
- Cenveo initiated with a Neutral at UBS
- 03/11/22 Canaccord
- Docebo price target lowered to $65 from $80 at Canaccord
- 02/01/22 Canaccord
- Docebo price target lowered to $80 from $95 at Canaccord
- 01/10/22 CIBC
- Docebo price target lowered to C$102 from C$125 at CIBC
- 12/02/21 Stifel
- Docebo initiated with a Buy at Stifel
DOC Physicians Realty Trust - 02/28/22 BMO Capital
- BMO can't rule out topping bid for Healthcare Trust
- 02/01/22 Credit Suisse
- Physicians Realty Trust initiated with a Neutral at Credit Suisse
- 01/07/22 BMO Capital
- Physicians Realty Trust downgraded to Market Perform from Outperform at BMO Capital
- 10/07/21 BMO Capital
- Healthcare Trust price target raised to $35 from $32.50 at BMO Capital
- 02/11/22 Needham
- ChannelAdvisor price target lowered to $26 from $35 at Needham
- 02/02/22 B. Riley
- ChannelAdvisor price target lowered to $32 from $38 at B. Riley
- 12/29/21 Baird
- Baird announces three new top internet stock picks for 2022
- 09/20/21 Needham
- ChannelAdvisor price target raised to $35 from $31 at Needham
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 02/16/22 Stifel
- Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
- 01/12/22 Stifel
- Equillium 'could be upside biased' into lupus nephritis data, says Stifel
- 10/29/21 Stifel
- Equillium resumed with a Buy at Stifel
- 03/22/22 UBS
- RealReal price target lowered to $9 from $17 at UBS
- 03/17/22 Jefferies
- RealReal initiated with a Buy at Jefferies
- 03/17/22 Jefferies
- RealReal initiated with a Buy at Jefferies
- 02/24/22 Wedbush
- RealReal price target lowered to $14 from $21 at Wedbush
- 02/23/22
- RealReal sees FY22 revenue $635M-$665M, consensus $597.61M
- 02/23/22
- RealReal sees Q1 revenue $130M-$140M, consensus $134.27M
- 02/23/22
- RealReal reports Q4 EPS (42c), consensus (38c)
- 02/23/22
- Notable companies reporting after market close
- 03/23/22
- Equillium reports Q4 EPS (36c), consensus (34c)
- 11/10/21
- Equillium reports Q3 EPS (35c), consensus (34c)
- 02/10/22
- ChannelAdvisor sees Q1 revenue $41.9M-$42.3M, consensus $42.07M
- 02/10/22
- ChannelAdvisor reports Q4 EPS $1.06 with items, consensus 24c
- 11/09/21
- ChannelAdvisor reports Q3 EPS 11c, consensus 17c
DOC Physicians Realty Trust - 02/23/22
- Physicians Realty Trust reports Q4 EPS 26c, consensus 26c
- 11/05/21
- Physicians Realty Trust reports Q3 normalized FFO 26c, consensus 26c
- 11/11/21
- Docebo reports Q3 EPS 2c, consensus (5c)
- 02/08/22
- CTS Corporation sees FY22 adjusted EPS $2.00-$2.25, consensus $2.09
- 02/08/22
- CTS Corporation reports Q4 adjusted EPS 49c, consensus 47c
- 10/27/21
- CTS Corporation raises 2021 adjusted EPS view $1.85-$1.95 from $1.70-$1.90
- 10/27/21
- CTS Corporation reports Q3 adjusted EPS 46c, consensus 39c
- 03/24/22
- Celestica sees 2022 revenue over $6.3B, consensus $6.34B
- 01/26/22
- Celestica sees FY22 revenue at least $6.3B, consensus $6.34B
- 01/26/22
- Celestica sees Q1 adjusted EPS 31c-37c
- 01/26/22
- Celestica reports Q4 adjusted EPS 44c, consensus 32c
- $192.69 /
+1.685 (+0.88%) - 02/22/22
- TopBuild sees 2022 revenue $4.5B-$4.65B, consensus $4.51B
- 02/22/22
- TopBuild reports Q4 adjusted EPS $3.12, consensus $2.92
- 11/02/21
- TopBuild sees FY21 revenue $3.425B-$3.475B, consensus $3.42B
- 11/02/21
- TopBuild reports Q3 adjusted EPS $2.95, consensus $3.04
- 02/08/22
- Absolute Software raises FY22 revenue view to $206M-$208M, consensus $206.04M
- 02/08/22
- Absolute Software reports Q2 EPS (10c), consensus (8c)
- 11/29/21
- Citron keeps $30 target on RealReal, sees possible takeout
- 11/24/21
- RealReal will be at $30 in next 12 months 'if not acquired first,' Citron tweets
- 03/22/22
- What You Missed On Wall Street On Tuesday
- 03/22/22
- What You Missed On Wall Street This Morning
- 11/29/21
- Wall Street in Fives - Must Read Lists for Monday
- 11/29/21
- Wall Street in Fives - Must Read Lists at Midday
- 01/04/22
- Game On: Square Enix sees NFTs in games as 'major trend'
- 03/24/22
- What You Missed On Wall Street On Thursday
- 03/24/22
- What You Missed On Wall Street This Morning
- 12/01/21
- Wall Street in Fives - Must Read Lists at Midday
- 02/23/22
- RealReal options imply 16.4% move in share price post-earnings
- 11/08/21
- RealReal options imply 15.0% move in share price post-earnings
DOC Physicians Realty Trust - 12/15/21
- Unusual call flow in option market yesterday
- 12/14/21
- Call buyer targets 4 month 9.5% upside in Physicians Realty Trust
|
Conference/Events
|
Global Healthcare Virtual… Global Healthcare Virtual Conference to be held on February 14-18. ShowHide Related Items >><< - 02/15/22
- Zynerba Chief Legal Officer Hanlon to retire, appoints Parker to position
- 11/22/21
- Zynerba announces issuance of new patent in EU for Zygel
- 11/15/21
- Zynerba expects cash to fund requirements well into 1H24
- 11/01/21
- BioVie announce appointment of new chief medical officer, Palumbo
- 12/02/21
- Zentalis to host R&D day on December 16
- 11/17/21
- Zentalis announces fast track designation granted by FDA to ZN-c3
- 11/10/21
- Zentalis expects cash to fund requirements into 3Q23
- 09/13/21
- Zentalis announces first patient dosed in Phase 1/2 study of ZN-c3
XENE Xenon Pharmaceuticals - 01/19/22
- Xenon Pharmaceuticals' flunarizine granted FDA orphan designation
- 01/12/22
- Xenon announces collaboration with Neurocrine achieves $15M milestone
- 01/10/22
- Xenon outlines key milestones for 2022
- 12/03/21
- Xenon Pharmaceuticals presents additional data from Phase 2b X-TOLE trial
- 11/10/21
- Wave Life Sciences announces upcoming clinical milestones
- 11/10/21
- Wave Life Sciences expects cash to fund requirements into 2Q23
- 10/18/21
- Wave Life Sciences, Takeda amend CNS collaboratyion
- 09/29/21
- Wave Life Sciences initiates dosing in Phase 1b/2a trial of WVE-N531
- 02/03/22
- Vincerx Pharma publishes preclinical data on VIP236
- 12/27/21
- Vincerx Pharma CFO buys $25K, Chief Business Officer buys $30K in common stock
- 12/17/21
- Vincerx Pharma doses first patient in Phase 1 dose-escalation study of VIP152
- 12/12/21
- Vincerx Pharma presents data on PTEFb/CDK9 inhibitor VIP152 in DLBCL, CLL
- 01/19/22
- Minerva Surgical Inc trading resumes
- 01/19/22
- Minerva Surgical Inc trading halted, volatility trading pause
- 12/02/21
- Minerva Surgical jumps over 10% to $6.40 after Q3 results
- 11/17/21
- Minerva Surgical launches educational website for abnormal uterine bleeding
- 01/24/22
- Tango Therapeutics announces clearance of TNG908 IND, pipeline progress
- 11/09/21
- Tango Therapeutics expects cash to fund operations into 2H24
- 11/01/21
- Tango Therapeutics appoints Marc Rudoltz as CMO, Doug Barry as general counsel
- 09/30/21
- Tango Therapeutics to present preclinical data on at AACR-NCI-EORTC 2021
- 01/12/22
- TCR2 Therapeutics names Rosemary Harrison as Chief Business and Strategy Officer
- 01/04/22
- TCR2 Therapeutics, Arbor establish collaboration for TRuc-T cell therapies
- 11/22/21
- TCR2 Therapeutics reports CFO to resign to pursue new opportunity
- 10/25/21
- TCR2 Therapeutics announces collaboration with Bristol-Myers
- 01/05/22
- Spruce Biosciences appoints Javier Szwarcberg, M.D. CEO
- 11/15/21
- Spruce Biosciences names Mike Grey interim CEO
SBTX Silverback Therapeutics - 09/16/21
- Silverback Therapeutics presents interim clinical results from SBT6050 trial
- 02/17/22
- Roche awarded $212.5M Army contract modification
- 02/11/22
- Roche announces Actemra/RoActemra granted WHO prequalification for severe COVID
- 02/11/22
- Genentech announces new two-year data from studies of Vabysmo, Susvimo
- 02/02/22
- Oncolytics and Roche's combination in pancreatic cancer shows positive safety
- 09/30/21
- Rapt Therapeutics presents results from Phase 1b trial of RPT193
- 02/08/22
- Rain Therapeutics announces key appointments to leadership team
- 01/05/22
- Rain Therapeutics, Roche to collaborate on trial of milademetan combination
- 12/14/21
- Rain Therapeutics added to Nasdaq Biotechnology Index
- 11/19/21
- Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan
- 02/07/22
- uniQure announces dosing of first patients in Phase Ib/II trial of AMT-130
- 12/16/21
- uniQure announces update on first patients in Phase I/II trial of AMT-130
- 12/09/21
- uniQure, CSL Behring announce primary endpoint reached in HOPE-B trial
- 11/02/21
- uniQure gets positive recommendation from DSMB in Phase I/II trial of AMT-130
- 02/07/22
- Quanterix's Simoa technology to power DRI neurodegenerative disease research
- 10/11/21
- FDA grants Quanterix breakthrough device designation for pTau-181 Assay in AD
- 09/13/21
- Quanterix gets label expansion on EUA for Simoa COVID antigen test
- 08/27/21
- Cassava says Quanterix testing conducted entirely by its employees
- 10/26/21
- Premier, Resilinc announce supply chain transparency collaboration
- 09/08/21
- Assure Holdings secures agreement with Premier
- 09/08/21
- Premier and 11 leading health systems invest in Exela for supply/manufacturing
- 09/07/21
- Premier decreases size of board, enhances corporate governance profile
- 02/16/22
- PacBio, KKH collaborate in study of unexplained neurodevelopmental disorders
- 01/13/22
- Pacific Biosciences appoints Lara Toerien as VP, General Manager for Americas
- 01/11/22
- PacBio, Genomics England collaborate to sequence biobanked rare disease samples
- 01/11/22
- PacBio, Berry Genomics collaborate for long read desktop sequencing
- 02/15/22
- OptimizeRx introduces new key performance indicators
- 12/22/21
- OptimizeRx CEO issues letter on completion of management changes
- 11/16/21
- OptimizeRx, Reuters Events to host second annual Innovate4Outcomes event
- 11/05/21
- OptimizeRx published analyst of multiple sclerosis
- 02/16/22
- Outset Medical names president and CEO Leslie Trigg as board chair
- 11/29/21
- Outset Medical says Tablo Hemodialysis System gets 510k clearance from FDA
- 11/01/21
- Outset Medical announces CMS approval for TPNIES for Tablo Hemodialysis System
- 01/11/22
- NeoGenomics subsidiary receives CE mark for its RaDaR assay
- 11/08/21
- Genetron, NeoGenomics partner to provide China focused trials
- 10/04/21
- NeoGenomics down 4% after Bloomberg says Guardant won't pursue deal
- 10/01/21
- NeoGenomics jumps at open after Bloomberg says Guardant Health exploring deal
NAUT Nautilus Biotechnology - 11/02/21
- Nautilus Biotechnology, Abcam partner for exploration of the proteome
- 08/26/21
- Nautilus Biotechnology director buys 37K shares of common stock
MIRM Mirum Pharmaceuticals - 11/17/21
- Mirum Pharmaceuticals sells Rare Pediatric Disease PRV for $110M
- 11/01/21
- Mirum Pharmaceuticals study of maralixibat in patients with ALGS published
- 09/29/21
- Mirum Pharmaceuticals up 7% following FDA approval of Livmarli
- 09/29/21
- Mirum Pharmaceuticals trading resumes
- 02/17/22
- Mednax sees 2022 adjusted EBITDA at least $270M
- 02/04/22
- Mednax acquires Night Lite Pediatrics, sees accretion
- 11/12/21
- Jeffrey Smith's Starboard Value buys Huntsman, exits Offerpad in Q3
- 02/01/22
- Lava Therapeutics treats first patient in Phase 1/2a clinical trial of LAVA-1207
- 01/18/22
- Lava Therapeutics presents preclinical data on Gammabody platform
- 10/15/21
- Lava Therapeutics receives orphan drug designation for LAVA-051
- 10/13/21
- Lava Therapeutics treatment of chronic lymphocytic leukemia gets orphan status
- 01/24/22
- KalVista publishes KVD900 data in JACI
- 11/10/21
- KalVista provides update on clinical trial progress for KVD900
- 11/08/21
- KalVista announces data at ACAAI from Phase 2 data for KVD900
- 09/14/21
- KalVista says FDA lifts clinical hold on Phase 2 clinical trial of KVD824
- 02/15/22
- Johnson & Johnson appoints Darius Adamczyk to board of directors
- 02/03/22
- Mersana announces research collaboration, license agreement with Janssen
- 02/02/22
- XBiotech executes manufacturing agreement with Janssen
- 02/01/22
- GSK's ViiV Healthcare announces FDA approval of Cabenuva label expansion
- 12/14/21
- Immatics and Bristol-Myers enter into an agreement for IMA401
- 11/16/21
- Immatics expects cash to fund operations into 2023
- 11/09/21
- Immatics reports data from Phase 1a trial of ACTengine IMA203
- 02/14/22
- Appaloosa takes stake in General Motors, exits position in HCA Healthcare
- 01/26/22
- HCA Healthcare to build five new hospitals in Texas
- 01/04/22
- HCA Healthcare purchases MD Now Urgent Care centers in FL, no terms
- 10/25/21
- HCA Healthcare announces Michael Cuffe as chief clinical officer
- 01/20/22
- Graybug Vision hires six to enhance R&D, Regulatory Affairs, Program Management
- 09/28/21
- Graybug Vision ends further development of GB-103 due to GB-102 results
- 09/28/21
- Graybug Vision reports analysis of data from ALTISSIMO Phase 2b trial
FULC Fulcrum Therapeutics - 02/11/22
- Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule
- 02/11/22
- Fulcrum Therapeutics' treatment of sickle cell disease gets orphan designation
- 01/10/22
- Fulcrum Therapeutics expects cash to fund requirements into 2024
- 01/10/22
- Fulcrum Therapeutics appoints Kate Haviland as chair of the board
- 02/10/22
- Homology Medicines to present on HMI-203 gene therapy candidate
- 01/28/22
- Homology Medicines, Oxford Biomedica to establish AAV business in the U.S.
- 10/21/21
- Homology Medicines announces presentations across gene therapy programs
- 10/20/21
- Homology Medicines announces presentation of data on MPS II, PKU
- 01/27/22
- Edwards Lifesciences falls -8.3%
- 12/20/21
- Edwards Lifesciences receives FDA approval for SAPIEN 3 with Alterra
- 12/08/21
- Edwards Lifesciences sees FY22 free cash flow $1.2B-$1.5B
- 12/08/21
- Edwards Lifesciences sees 2022 TAVR sales $3.7B-$4B; underlying growth 12%-15%
- 02/16/22
- Equillium acquires Bioniz Therapeutics, announced departure of CMO Dolca Thomas
- 11/02/21
- Equillium data shows itolizumab is well tolerated, reduces proteinuria
- 01/18/22
- Codex DNA showcases potential of SOLA EDS approach
- 01/10/22
- Codex DNA signs collaboration and licensing agreement with Pfizer
- 12/30/21
- Codex DNA, Pfizer enter license agreement with $8M upfront payment
- 12/23/21
- Codex DNA releases full-lenfth synthetic genome for SARS-CoV-2 omicron variant
- 11/12/21
- Dice Therapeutics expects cash to fund operations through 2023
- 10/25/21
- Dice Therapeutics initiates Phase 1 clinical trial of S011806
- 01/19/22
- ChemoCentryx announces EU approval of TAVNEOS
- 11/12/21
- ChemoCentryx receives positive recommendation for use of TAVNEOS by EMA
- 11/04/21
- ChemoCentryx announces abstracts accepted for presentations at ASN, ACR
- 10/11/21
- ChemoCentryx appoints Rita Jain as Executive VP, CMO
CALA Calithera Biosciences - 11/05/21
- Calithera Biosciences promotes Emil Kuriakose to Chief Medical Officer
- 11/05/21
- Calithera Biosciences announces decision to discontinue KEAPSAKE trial
- 11/01/21
- Calithera Biosciences presents interim data from Phase 1b trial of CB-280
- 10/21/21
- Calithera Biosciences to present first clinical data on CB-280 at NACFC
- 01/18/22
- Bluebird Bio falls after FDA extends review for biologics licensing applications
- 01/18/22
- VBL Therapeutics appoints Matthew Trudeau as CCO
- 01/11/22
- Bluebird Bio cash, cash and cash equivalents $442M at year-end
- 01/11/22
- Bluebird Bio provides update on program milestones
- 01/10/22
- Pfizer, Beam Therapeutics announce four-year research collaboration
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 11/12/21
- Beam Therapeutics reports preclinical data for multiplex edited CAR T cells
- 10/19/21
- Sana obtains non-exlusive license to CRISPR Cas12b gene editing technology
- 01/27/22
- Adagene doses first patient in combination cohort of ADG106 with ADG116
- 01/25/22
- Adagene Inc (ADS) trading resumes
- 01/25/22
- Adagene Inc (ADS) trading halted, volatility trading pause
- 01/19/22
- Adagene expands the SAB with appointment of Gandara
- 10/07/21
- Accolade completes asset acquisition of AI firm HealthReveal
- 09/21/21
- Amwell appoints Robert Shepardson as CFO
- 02/11/22 Goldman Sachs
- Accolade initiated with a Buy at Goldman Sachs
- 01/11/22 BTIG
- Accolade price target lowered to $35 from $60 at BTIG
- 01/11/22 Stifel
- Accolade price target lowered to $34 from $40 at Stifel
- 01/11/22 Canaccord
- Accolade price target lowered to $34 from $52 at Canaccord
- 01/05/22 Wells Fargo
- Avrobio price target lowered to $8 from $36 at Wells Fargo
- 12/06/21 Cowen
- Cowen starts Crispr at Market Perform as applications 'need maturing'
- 11/12/21 BMO Capital
- Bluebird Bio price target lowered to $13 from $21 at BMO Capital
- 11/08/21 Canaccord
- 2seventy Bio initiated with a Buy at Canaccord
- 11/15/21 Raymond James
- InflaRx's ANCA vasculitis data 'solid,' says Raymond James
- 11/10/21 Raymond James
- ChemoCentryx price target raised to $110 from $107 at Raymond James
- 10/11/21 JPMorgan
- ChemoCentryx upgraded to Neutral from Underweight at JPMorgan
- 10/11/21 SVB Securities
- ChemoCentryx upgraded to Outperform from Market Perform at SVB Leerink
- 12/30/21 KeyBanc
- Pfizer deal provides key validation of Codex DNA's technology, says KeyBanc
- 10/14/21 Cowen
- Codex DNA coverage transferred at Cowen
- 07/13/21 Cowen
- Cowen starts 'promising' Codex DNA at Outperform
- 07/13/21 Jefferies
- Jefferies starts 'discounted' Codex DNA at Buy with $23 price target
- 01/27/22 Raymond James
- Edwards Lifesciences price target lowered to $126 from $134 at Raymond James
- 01/27/22 Piper Sandler
- Edwards Lifesciences price target lowered to $125 from $133 at Piper Sandler
- 01/07/22 Credit Suisse
- Edwards Lifesciences price target raised to $144 from $131 at Credit Suisse
- 01/03/22 JPMorgan
- JPMorgan says own these medical device stocks into next week's conference
- 09/07/21 Oppenheimer
- BioMarin clinical hold has little read through to Homology, says Oppenheimer
- 05/18/21 Canaccord
- Homology Medicines price target lowered to $19 from $37 at Canaccord
- 05/07/21 Oppenheimer
- Homology Medicines price target lowered to $24 from $27 at Oppenheimer
- 04/28/21 Stifel
- Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
- 12/15/21 Wedbush
- Graybug Vision assumed with a Neutral, $3 target at Wedbush
- 12/15/21 Wedbush
- Graybug Vision assumed with a Neutral at Wedbush
- 05/13/21
- Fly Intel: Top five analyst downgrades
- 05/13/21 Cantor Fitzgerald
- Graybug Vision price target lowered to $6 from $14 at Cantor Fitzgerald
- 02/07/22 BofA
- BOFA adds Zoetis and Microsoft to best ideas list, removes two
- 01/31/22 BMO Capital
- HCA Healthcare price target lowered to $250 from $275 at BMO Capital
- 01/31/22 Citi
- HCA Healthcare price target lowered to $277 from $306 at Citi
- 01/28/22 Cowen
- HCA Healthcare price target lowered to $265 from $302 at Cowen
- 12/14/21 SVB Securities
- SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
- 12/14/21 SVB Securities
- Immatics price target raised to $32 from $28 at SVB Leerink
- 03/17/21 Chardan
- Immatics' early TCR platform activity signals 'notable,' says Chardan
- 03/17/21 SVB Securities
- Immatics price target raised to $26 from $17 at SVB Leerink
- 01/26/22 Raymond James
- Johnson & Johnson price target raised to $185 from $178 at Raymond James
- 01/25/22 Citi
- Johnson & Johnson quarter reflected 'resilience,' says Citi
- 12/29/21 Credit Suisse
- Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
- 12/17/21
- Fly Intel: Top five analyst initiations
- 11/10/21 Roth Capital
- KalVista FDA meeting feedback 'quite positive,' says Roth Capital
- 08/23/21 Roth Capital
- KalVista could take 'substantial' share of HAE market, says Roth Capital
- 04/20/21 Roth Capital
- KalVista selloff seems overdone after clinical hold, says Roth Capital
- 04/19/21 SVB Securities
- SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
- 04/19/21 JPMorgan
- Lava Therapeutics initiated with an Overweight at JPMorgan
- 04/19/21 Jefferies
- Lava Therapeutics initiated with a Buy at Jefferies
- 04/19/21 SVB Securities
- Lava Therapeutics initiated with an Outperform at SVB Leerink
- 12/20/21 Mizuho
- Mednax price target lowered to $28 from $32 at Mizuho
- 11/01/21 BMO Capital
- Mednax price target lowered to $31 from $37 at BMO Capital
- 10/13/21 Truist
- Mednax price target lowered to $31 from $37 at Truist
- 09/27/21 SVB Securities
- SVB Leerink starts Mednax at Market Perform with $29 price target
NAUT Nautilus Biotechnology - 01/06/22 Morgan Stanley
- Nautilus Biotechnology initiated with an Equal Weight at Morgan Stanley
- 11/02/21 Cowen
- Cowen starts Nautilus Biotechnology with Outperform, Proteomics potential seen
- 11/02/21 Cowen
- Nautilus Biotechnology initiated with an Outperform at Cowen
- 08/03/21 Goldman Sachs
- Nautilus Biotechnology initiated with a Neutral at Goldman Sachs
- 02/17/22 Morgan Stanley
- Outset Medical upgraded at Morgan Stanley on inflecting Home opportunity
- 02/17/22 Cowen
- Outset Medical price target lowered to $60 from $70 at Cowen
- 08/27/21 BofA
- Outset Medical remains a 'top idea' at BofA
- 08/23/21 Cowen
- CMS rule comments show clear support for Outset's Tablo, says Cowen
- 11/18/21 Barclays
- Premier price target raised to $36 from $34 at Barclays
- 11/03/21 Piper Sandler
- Premier price target raised to $39 from $31 at Piper Sandler
- 05/28/21
- Fly Intel: Top five analyst downgrades
- 05/28/21 Barclays
- Barclays double downgrades Premier with multiple expansion less likely
- 12/16/21 Raymond James
- uniQure downgraded to Outperform at Raymond James after Huntington's data update
- 12/16/21 Raymond James
- uniQure downgraded to Outperform from Strong Buy at Raymond James
- 12/16/21 H.C. Wainwright
- uniQure selloff on Huntington's data 'overdone,' says H.C. Wainwright
- 10/27/21 William Blair
- uniQure initiated with an Outperform at William Blair
- 01/03/22 Guggenheim
- Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
- 11/10/21 Piper Sandler
- Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
- 09/14/21
- Fly Intel: Top five analyst downgrades
- 09/14/21 Goldman Sachs
- Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
SBTX Silverback Therapeutics - 07/07/21 H.C. Wainwright
- Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
- 05/27/21
- Fly Intel: Top five analyst initiations
- 05/27/21 JonesTrading
- Silverback Therapeutics initiated with a Buy at JonesTrading
- 03/30/21 Goldman Sachs
- Silverback price target raised to $48 from $43 at Goldman Sachs
- 12/16/21 Oppenheimer
- Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
- 12/16/21 Oppenheimer
- Spruce Biosciences initiated with an Outperform at Oppenheimer
- 12/10/21 Benchmark
- Spruce Biosciences initiated with a Speculative Buy at Benchmark
- 11/23/21 Cowen
- Spruce Biosciences downgraded to Market Perform from Outperform at Cowen
- 09/20/21 SVB Securities
- SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform
- 09/20/21 SVB Securities
- Tango Therapeutics initiated with an Outperform at SVB Leerink
- 09/07/21
- Fly Intel: Top five analyst initiations
- 09/07/21 Wedbush
- Tango Therapeutics initiated with an Outperform at Wedbush
- 01/14/22 Piper Sandler
- Piper tells small cap investors to buy basket of recent med tech IPOs
- 12/03/21 Piper Sandler
- Piper 'strongly' encourages buying Minerva shares after Q3 print
- 11/16/21
- Fly Intel: Top five analyst initiations
- 11/16/21 SVB Securities
- SVB Leerink bullish on Minerva Surgical, initiates with an Outperform
- 06/25/21 Alliance Global Partners
- Cannabis selloff brings buying opportunities, says Alliance Global
- 05/06/21 Cantor Fitzgerald
- Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
- 03/29/21 Stifel
- Stifel says New York adult use cannabis market represents $5B opportunity
- 03/10/21 Roth Capital
- Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
- 02/01/22 Morgan Stanley
- Adagene price target lowered to $15 from $27 at Morgan Stanley
- 06/25/21
- Fly Intel: Top five analyst initiations
- 06/25/21 China Renaissance
- Adagene initiated with a Buy, $40.57 target at China Renaissance
- 06/24/21 China Renaissance
- Adagene initiated with a Buy at China Renaissance
- 01/10/22 Wedbush
- Beam Therapeutics price target raised to $159 from $148 at Wedbush
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 10/19/21 SVB Securities
- Beam Therapeutics initiated with an Outperform at SVB Leerink
CALA Calithera Biosciences - 01/31/22 Ladenburg
- Calithera initiated with Buy, $4 price target at Ladenburg
- 01/31/22 Ladenburg
- Calithera Biosciences initiated with a Buy at Ladenburg
- 01/20/22 SVB Securities
- Calithera Biosciences upgraded to Outperform from Market Perform at SVB Leerink
- 11/08/21 William Blair
- Calithera downgraded to Market Perform at William Blair after trial miss
- 10/11/21 SVB Securities
- Dice Therapeutics initiated with an Outperform at SVB Leerink
- 10/11/21 Evercore ISI
- Evercore ISI starts Dice Therapeutics at Outperform, sees 120% upside
- 10/11/21 BofA
- Dice Therapeutics initiated with a Buy at BofA
- 10/11/21 Evercore ISI
- Dice Therapeutics initiated with an Outperform at Evercore ISI
- 02/16/22 Stifel
- Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
- 01/12/22 Stifel
- Equillium 'could be upside biased' into lupus nephritis data, says Stifel
- 10/29/21 Stifel
- Equillium resumed with a Buy at Stifel
- 09/15/21
- Fly Intel: Top five analyst initiations
FULC Fulcrum Therapeutics - 01/06/22 Stifel
- Fulcrum pullback due to headline with 'inaccurate information,' says Stifel
- 08/17/21 Piper Sandler
- Fulcrum Therapeutics price target raised to $46 from $20 at Piper Sandler
- 08/17/21 H.C. Wainwright
- Fulcrum Therapeutics price target raised to $40 from $20 at H.C. Wainwright
- 08/11/21 Credit Suisse
- Fulcrum Therapeutics price target raised to $30 from $20 at Credit Suisse
MIRM Mirum Pharmaceuticals - 10/11/21 Piper Sandler
- Mirum Pharmaceuticals remains undervalued despite catalysts, says Piper Sandler
- 09/30/21 H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $64 from $51 at H.C. Wainwright
- 09/30/21 Raymond James
- Mirum Pharmaceuticals price target raised to $69 from $51 at Raymond James
- 09/30/21 Baird
- Mirum Pharmaceuticals price target raised to $34 from $30 at Baird
- 01/18/22 Stephens
- NeoGenomics assumed with an Overweight at Stephens
- 12/16/21 Cowen
- NeoGenomics initiated with an Outperform at Cowen
- 12/07/21 Needham
- NeoGenomics price target lowered to $41 from $48 at Needham
- 11/05/21 Morgan Stanley
- Morgan Stanley downgrades NeoGenomics, sees limited near-term upside
- 02/16/22 Lake Street
- OptimizeRx price target lowered to $76 from $98 at Lake Street
- 01/24/22 William Blair
- William Blair sees 'compelling' entry points for two healthcare tech names
- 12/27/21 B. Riley
- B. Riley recommends LifeMD, OptimizeRx, Semler, Zynex into 2022
- 11/10/21 Roth Capital
- OptimizeRx price target raised to $112 from $85 at Roth Capital
- 02/16/22 Canaccord
- Pacific Biosciences price target lowered to $40 from $45 at Canaccord
- 01/21/22 Cantor Fitzgerald
- Pacific Biosciences assumed with an Overweight at Cantor Fitzgerald
- 01/11/22 Piper Sandler
- Pacific Biosciences has new competitor in Illumina, says Piper Sandler
- 01/05/22 Piper Sandler
- Pacific Biosciences assumed with a Neutral at Piper Sandler
- 10/14/21 Cowen
- Quanterix coverage transferred at Cowen
- 06/04/21
- Fly Intel: Top five analyst initiations
- 06/04/21 Goldman Sachs
- Quanterix initiated with a Sell at Goldman Sachs
- 05/06/21 SVB Securities
- Quanterix price target lowered to $70 from $85 at SVB Leerink
- 12/09/21 JPMorgan
- Rapt Therapeutics initiated with an Overweight at JPMorgan
- 11/16/21 Cantor Fitzgerald
- Rapt Therapeutics price target lowered to $58 from $71 at Cantor Fitzgerald
- 08/12/21 SVB Securities
- Rapt Therapeutics initiated with an Outperform at SVB Leerink
- 07/12/21 Roth Capital
- Roth adds more 'SMID-cap' names to second half top picks
- 02/11/22 H.C. Wainwright
- Regeneron's Eylea data 'turns up heat' in wet AMD fight, says H.C. Wainwright
- 01/14/22 BofA
- Biogen price target lowered to $245 from $275 at BofA
- 01/04/22 JPMorgan
- Roche price target raised to CHF 390 from CHF 360 at JPMorgan
- 12/22/21 Citi
- Roche resumed with a Buy at Citi
- 01/19/22 Goldman Sachs
- TCR2 Therapeutics assumed with Neutral from Buy at Goldman Sachs
- 01/13/22 H.C. Wainwright
- TCR2 Therapeutics price target lowered to $19 from $25 at H.C. Wainwright
- 11/29/21 Piper Sandler
- TCR2 Therapeutics recent selloff brings buying opportunity, says Piper Sandler
- 11/18/21 Piper Sandler
- TCR2 Therapeutics transferred with an Overweight at Piper Sandler
- 01/14/22 H.C. Wainwright
- Vincerx Pharma initiated with a Buy at H.C. Wainwright
- 12/23/21
- Fly Intel: Top five analyst initiations
- 12/23/21 Cantor Fitzgerald
- Vincerx Pharma initiated with an Overweight at Cantor Fitzgerald
- 12/23/21 Cantor Fitzgerald
- Vincerx Pharma initiated with an Overweight at Cantor Fitzgerald
- 05/19/21 Mizuho
- Wave Life Sciences price target raised to $8 from $7 at Mizuho
- 03/30/21 Truist
- Wave Life Sciences price target lowered to $17 from $27 at Truist
- 03/30/21 Mizuho
- Wave Life Sciences price target lowered to $7 from $21 at Mizuho
- 03/30/21 RBC Capital
- Wave Life Sciences price target lowered to $8 from $13 at RBC Capital
XENE Xenon Pharmaceuticals - 11/11/21 SVB Securities
- Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
- 10/28/21 RBC Capital
- Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
- 10/06/21 Wedbush
- Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
- 10/04/21 Jefferies
- Jefferies ups Xenon target to $50 after 'home run' epilepsy data
- 11/11/21 H.C. Wainwright
- Zentalis price target raised to $120 from $80 at H.C. Wainwright
- 10/28/21 SVB Securities
- Zentalis price target raised to $84 from $64 at SVB Leerink
- 10/27/21 Wedbush
- Zentalis price target raised to $89 from $65 at Wedbush
- 10/19/21 Morgan Stanley
- Zentalis assumed with an Overweight at Morgan Stanley
- 11/15/21
- Zynerba reports Q3 EPS (26c), consensus (25c)
- 11/10/21
- Zentalis reports Q3 EPS (9c), consensus ($1.31)
XENE Xenon Pharmaceuticals - 11/10/21
- Xenon Pharmaceuticals reports Q3 EPS (36c), consensus (38c)
- 11/10/21
- Wave Life Sciences reports Q3 EPS (12c), consensus (63c)
- 11/12/21
- Vincerx Pharma reports Q3 EPS ($1.39), consensus (85c)
- 01/11/22
- Minerva Surgical sees FY21 revenue $52M - $52.2M, consensus $51.75M
- 01/11/22
- Minerva reports preliminary Q4 revenue $13.5M - $13.7M, consensus $13.4M
- 12/02/21
- Minerva Surgical sees FY21 revenue $51.0M-$52.0M, consensus $51.7M
- 12/02/21
- Minerva Surgical reports Q3 EPS ($1.15), consensus (44c)
- 11/09/21
- Tango Therapeutics reports Q3 EPS (28c), consensus (28c)
- 11/10/21
- TCR2 Therapeutics reports Q3 EPS *69c), consensus (65c)
SBTX Silverback Therapeutics - 11/10/21
- Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
- 02/03/22
- Roche sees FY22 core earnings growing in low- to mid-single digit range
- 02/03/22
- Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16
- 10/20/21
- Roche reports 9M group sales CHF 46.68B vs. CHF 43.98B last year
- 11/10/21
- Rain Therapeutics reports Q3 EPS (70c), consensus (48c)
- 10/25/21
- uniQure reports Q3 EPS (79c), consensus ($1.05)
- 01/13/22
- Quanterix sees FY21 revenue $109M-$111M, consensus $105.54M
- 01/13/22
- Quanterix reports preliminary Q4 revenue $29M-$31M, consensus $27.08M
- 11/04/21
- Quanterix reports Q3 net loss ($15.67M) vs. $2.2M last year
- 02/01/22
- Premier lowers FY22 adjusted EPS view to $2.45-$2.55 from $2.56-$2.66
- 02/01/22
- Premier reports Q2 adjusted EPS 73c, consensus 65c
- 11/02/21
- Premier raises FY22 adjusted EPS view to $2.56-$2.66 from $2.50-$2.60
- 11/02/21
- Premier reports Q1 adjusted EPS 64c, consensus 59c
- 02/15/22
- Pacific Biosciences reports Q4 EPS (30c), consensus (28c)
- 01/11/22
- Pacific Biosciences sees 2021 revenue $130.5M, consensus $131.27M
- 01/11/22
- Pacific Biosciences sees Q4 revenue $36M, consensus $36.58M
- 11/02/21
- Pacific Biosciences reports Q3 EPS (23c), consensus (22c)
- 02/15/22
- OptimizeRx sees 2022 revenue $80M-$85M, consensus $81.59M
- 02/15/22
- OptimizeRx sees Q4 revenue $20.3M, consensus $20.24M
- 11/09/21
- OptimizeRx reports Q3 EPS 9c, consensus 13c
- 02/16/22
- Outset Medical sees FY22 revenue $142M-$160M, consensus $140.44M
- 02/16/22
- Outset Medical reports Q4 adjusted EPS (77c), consensus (77c)
- 11/03/21
- Outset Medical raises FY21 revenue guidance to $99M-$101M from $97M-$100M
- 11/03/21
- Outset Medical reports Q3 EPS (59c), consensus (73c)
NAUT Nautilus Biotechnology - 11/02/21
- Nautilus Biotechnology reports Q3 EPS (12c), consensus (10c)
MIRM Mirum Pharmaceuticals - 11/15/21
- Mirum Pharmaceuticals reports Q3 EPS ($1.55), consensus ($1.73)
- 02/17/22
- Mednax reports Q4 adjusted EPS 52c, consensus 44c
- 10/28/21
- Mednax reports Q3 non-GAAP EPS 46c, consensus 42c
- 11/15/21
- Lava Therapeutics reports Q3 EPS (EUR 0.23) vs. (EUR 8.43) last year
- 12/09/21
- KalVista reports Q2 EPS (80c), consensus (79c)
- 09/09/21
- KalVista reports Q1 EPS (66c), consensus (71c)
- 01/25/22
- Johnson & Johnson sees FY22 adjusted EPS $10.40-$10.60, consensus $10.37
- 01/24/22
- Notable companies reporting before tomorrow's open
- 10/19/21
- Johnson & Johnson raises FY21 adjusted EPS view to $9.65-$9.70 from $9.50-$9.60
- 11/16/21
- Immatics reports Q3 EPS (EUR 0.43) vs (EUR 2.61) last year
- 01/27/22
- HCA Healthcare sees FY22 EPS $18.40-$19.20, consensus $18.73
- 01/27/22
- HCA Healthcare reports Q4 EPS $5.75, consensus $4.53
- 01/26/22
- Notable companies reporting before tomorrow's open
- 11/11/21
- Graybug Vision reports Q3 EPS (38c), consensus (37c)
FULC Fulcrum Therapeutics - 11/04/21
- Fulcrum Therapeutics sees cash, cash equivalents fund into 2024
- 11/04/21
- Fulcrum Therapeutics reports Q3 EPS (57c), consensus (65c)
- 11/15/21
- Homology Medicines reports Q3 EPS (54c), consensus (60c)
- 01/26/22
- Edwards Lifesciences backs FY22 adjusted EPS $2.50-$2.65, consensus $2.58
- 01/26/22
- Edwards Lifesciences sees Q1 adjusted EPS 54c-62c, consensus 60c
- 01/26/22
- Edwards Lifesciences reports Q4 EPS 51c, consensus 55c
- 01/26/22
- Notable companies reporting after market close
- 11/10/21
- Equillium reports Q3 EPS (35c), consensus (34c)
- 11/09/21
- Codex DNA reports Q3 EPS (34c), consensus (28c)
- 11/12/21
- Dice Therapeutics reports Q3 EPS ($2.30), one est. (50c)
- 11/09/21
- ChemoCentryx reports Q3 EPS (32c), consensus (45c)
CALA Calithera Biosciences - 11/09/21
- Calithera Biosciences reports Q EPS (15c), consensus (23c)
- 11/05/21
- Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60)
- 11/05/21
- Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60)
- 11/08/21
- Beam Therapeutics reports Q3 EPS (42c), consensus (74c)
- 08/26/21
- Adagene reports 1H non-GAAP EPS (59c) vs. (70c) last year
- 01/11/22
- Accolade sees FY23 revenue growth of about 25% vs. FY22
- 01/10/22
- Accolade sees FY22 revenue growth of 25% over fiscal year 2022
- 01/10/22
- Accolade sees Q4 revenue $90M-$93M, consensus $97.71M
- 01/10/22
- Accolade reports Q3 EPS 31c, consensus (74c)
|